Key Market Indicator:
F&G: 55
25.562,04 NASDAQ · 49.131,99 DOW · 6.906,59 S&P · 4.980,35 Gold · 65,10 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
© EQS Newswire
26.01.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma erreicht Jahresziele für 2023 und setzt profitablen Wachstumskurs fort
Article
News Preview
SCHOTT Pharma erreicht Jahresziele für 2023 und setzt profitablen Wachstumskurs fort Geschäftsjahr 2023: Umsatzwachstum von 9 % gegenüber Vorjahr auf 899 Millionen Euro, EBITDA-Anstieg um 9 % auf 239 Millionen Euro, weiterhin hohe EBITDA-Marge von 26,6 % Strategische Ausrichtung auf margenstarke High-Value-Lösungen weiter beschleunigt; Umsatzant......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.01.2024
ISIN: DE000A3ENQ51
SCHOTT Pharma AG & Co KgaA
1SXP
LISTED
XETR
SCHOTT Pharma delivers on 2023 targets and continues profitable growth trajectory
Article
News Preview
SCHOTT Pharma delivers on 2023 targets and continues profitable growth trajectory FY 2023: Revenues up 9% yoy to EUR 899m, EBITDA increase of 9% to EUR 239m, maintaining high EBITDA margin of 26.6% Strategic shift towards strong-margin high-value solutions (HVS) further accelerated, representing 48% of full year revenues For FY 2024, SCHOTT Pha......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.01.2024
ISIN: DE0007165607
Sartorius AG
SRT
LISTED
XETRA
Sartorius expects profitable growth in 2024; double-digit annual sales revenue growth projected through to 2028
Article
News Preview
Göttingen, January 26, 2024 Sartorius expects profitable growth in 2024; double-digit annual sales revenue growth projected through to 2028   Preliminary 2023 results in line with forecast: sales revenue in constant currencies down 16.6 percent; underlying EBITDA margin of 28.3 percent Demand recovery in both divisions in the fourth quarter: ord......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© EQS Newswire
26.01.2024
ISIN: DE0007165607
Sartorius AG
SRT
LISTED
XETRA
Sartorius erwartet für 2024 profitables Wachstum; Umsatz soll bis 2028 pro Jahr zweistellig steigen
Article
News Preview
Göttingen, 26. Januar 2024 Sartorius erwartet für 2024 profitables Wachstum; Umsatz soll bis 2028 pro Jahr zweistellig steigen   Vorläufige Geschäftsergebnisse für das Jahr 2023 im Rahmen der Prognose: Umsatz wechselkursbereinigt -16,6 Prozent; operative EBITDA-Marge erreicht 28,3 Prozent Nachfragebelebung in beiden Konzernsparten im 4. Quartal:......
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
25.01.2024
ISIN: GB00BMX86B70
Haleon PLC
HLN
LISTED
LSE
Yellow Wood Partners Portfolio Company Suave Brands Company Acquires ChapStick from Haleon
Article
News Preview
BOSTON, Jan. 25, 2024 /PRNewswire/ -- Yellow Wood Partners ("Yellow Wood"), a Boston-based private equity firm focused on investing in consumer brands and companies, today announced that its portfolio company Suave Brands Company has signed a binding offer to acquire the ChapStick brand from Haleon (LSE / NYSE: HLN), a global leader in consumer h...
Themefolio
Profiler
Peergroup
© Newsfile
25.01.2024
ISIN: NL0011832936
Cosmo Pharmaceuticals NV
COPN
LISTED
SIX
Invitation to Cosmo's Investor Day and Full-Year 2023 Webcast - Zurich, 20 March 2024
Article
News Preview
Dublin, Ireland--(Newsfile Corp. - January 25, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced today that it will publish its Full-Year 2023 results on Wednesday, 20 March 2024 at 7:00 am CET. FY 2023 Results Webcast Cosmo invites investors, financial analysts and busine...
Themefolio
Profiler
Peergroup
© EQS Newswire
23.01.2024
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Eckert & Ziegler und Full-Life Technologies unterzeichnen Actinium-225 Liefervertrag für Radiopharmazeutika der nächsten Generation
Article
News Preview
Berlin, Deutschland und Gembloux, Belgien – 23. Januar 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) und Full-Life Technologies (Full-Life), ein in der klinischen Phase befindliches, voll integriertes und global agierendes Radiotherapeutika-Unternehmen, gaben heute bekannt, dass sie einen Vertrag über die Lieferung von Actinium-225 (Ac-225)......
Themefolio
Profiler
Peergroup
© EQS Newswire
23.01.2024
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Eckert & Ziegler and Full-Life Technologies Sign Actinium-225 Supply Agreement for Next Generation Radiopharmaceuticals
Article
News Preview
Berlin, Germany and Gembloux, Belgium – 23 January 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and Full-Life Technologies (Full-Life), a clinical stage, fully integrated global radiotherapeutics company today announced they have entered into an agreement for the supply of Actinium-225 (Ac-225). The agreement provides Full-Life with access......
Themefolio
Profiler
Peergroup
© EQS Newswire
22.01.2024
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Invitation to Conference Call
Article
News Preview
Hamburg, Germany, 22 January 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) is going to hold a conference call to provide a statement as well as a business update on Monday, 22 January 2024. During the call, the Chairwoman of Evotec’s Supervisory Board, Prof. Iris Löw-Friedrich and Evotec’s CEO Dr Mari......
Themefolio
Profiler
Peergroup
© EQS Newswire
22.01.2024
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Einladung zu Telefonkonferenz
Article
News Preview
Hamburg, 22. Januar 2024: Die Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) wird am Montag, den 22. Januar 2024, eine Telefonkonferenz abhalten, um eine Stellungnahme abzugeben und über die aktuelle Geschäftsentwicklung zu berichten. Im Rahmen der Telefonkonferenz werden die Vorsitzende des Aufsichtsrats......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.01.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon Ranibizumab Biosimilar FYB201/CIMERLI® achieved a market share of 38% in the United States in December 2023
Article
News Preview
Press Release // January 18, 2024   Formycon Ranibizumab Biosimilar FYB201/CIMERLI® achieved a market share of 38% in the United States in December 2023   Munich, Germany – Formycon AG (FWB: FYB) today announced that its commercialization partner, Coherus BioSciences, Inc. has released new sales figures for CIMERLI®1 (Ranibizumab-eqrn) in the US......
Themefolio
Profiler
Peergroup
© EQS Newswire
18.01.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycons Ranibizumab Biosimilar FYB201/CIMERLI® erreicht im Dezember 2023 einen Marktanteil von 38% in den USA
Article
News Preview
Pressemitteilung // 18. Januar 2024   Formycons Ranibizumab Biosimilar FYB201/CIMERLI® erreicht im Dezember 2023 einen Marktanteil von 38% in den USA   München – Formycon AG (FWB: FYB) gab heute bekannt, dass ihr Vermarktungspartner Coherus BioSciences, Inc.  neue Verkaufszahlen zu CIMERLI®1 (Ranibizumab-eqrn) in den USA veröffentlicht hat. Demn......
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
16.01.2024
ISIN: GB00BMX86B70
Haleon PLC
HLN
LISTED
LSE
Advil presents an in-game solution to fight gaming headaches
Article
News Preview
MISSISSAUGA, ON, Jan. 16, 2024 /CNW/ - Advil is helping Canadians who love to game, play at their best with Advil Head Settings – a series of genre-based guidelines that empower gamers of all levels to fine-tune their in-game PC settings, effectively reducing the onscreen stimulation that can lead to headaches. Designed for gaming genres with the...
Themefolio
Profiler
Peergroup
© EQS Newswire
11.01.2024
ISIN: DE0005313704
Carl Zeiss Meditec AG
AFX
LISTED
XETR
U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS
Article
News Preview
U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS   The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements. DUBLIN, CA (USA) / JENA, Germany | January 11, 2024 | Carl Zeiss Meditec AG ZEISS Medical Technology announced today tha......
Themefolio
Profiler
Peergroup
© EQS Newswire
11.01.2024
ISIN: DE0005313704
Carl Zeiss Meditec AG
AFX
LISTED
XETR
VISUMAX 800 mit SMILE pro Software von ZEISS erhält FDA-Zulassung in den USA
Article
News Preview
VISUMAX 800 mit SMILE pro Software von ZEISS erhält FDA-Zulassung in den USA   Die neueste Generation des ZEISS Femtosekundenlasers bietet der Refraktivchirurgie schnellere Behandlungsmöglichkeiten, größere Flexibilität und einen verbesserten klinischen Arbeitsablauf.  Jena / Deutschland | Dublin / USA | 11. Januar 2024 Heute gibt die Medizi......
Themefolio
Profiler
Peergroup
© EQS Newswire
10.01.2024
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec and Crohn´s & Colitis Foundation enter agreement to advance drug discovery for novel IBD therapies
Article
News Preview
EVOTEC JOINS FORCES WITH THE CROHN’S & COLITIS FOUNDATION’S IBD THERAPEUTICS INCUBATOR TO ADVANCE DRUG DISCOVERY AND IDENTIFY NOVEL THERAPIES FOR INFLAMMATORY BOWEL DISEASE (“IBD”) THE COLLABORATION LEVERAGES EVOTEC'S END-TO-END INTEGRATED R&D PLATFORM TO ADVANCE DRUG DISCOVERY FOR TWO INNOVATIVE DRUG TARGETS ADDRESSING FIBROSIS AND IMPAIR......
Themefolio
Profiler
Peergroup
© EQS Newswire
10.01.2024
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec und Crohn´s & Colitis Foundation gehen Vereinbarung zur Förderung der Wirkstoffforschung für neue IBD Therapien ein
Article
News Preview
EVOTEC SCHLIESST SICH MIT DEM IBD THERAPEUTICS INCUBATOR PROGRAMM DER CROHN’S & COLITIS FOUNDATION ZUSAMMEN, UM DIE WIRKSTOFFFORSCHUNG FÜR ENTZÜNDLICHE DARMERKRANKUNGEN („IBD“) VORANZUTREIBEN UND NEUE THERAPIEANSÄTZE ZU IDENTIFIZIEREN DIE KOLLABORATION NUTZT EVOTECS INTEGRIERTE END-TO-END F&E-PLATTFORM, UM DIE WIRKSTOFFFORSCHUNG FÜR ZWEI I......
Themefolio
Profiler
Peergroup
© Newsfile
09.01.2024
ISIN: US83086J2006
Skye Bioscience Inc
SKYE
LISTED
NASDAQ
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
Article
News Preview
Phase 2 trial to assess impact of peripherally-acting CB1 inhibitor on weight loss and metabolic biomarkers related to co-morbid obesity and chronic kidney diseaseSan Francisco, California--(Newsfile Corp. - January 9, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing drugs targeting the endo...
Themefolio
Profiler
Peergroup
© EQS Newswire
08.01.2024
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Eckert & Ziegler und ARTBIO vereinbaren Partnerschaft zur Herstellung und Lieferung von Blei-212 Verbindungen
Article
News Preview
Berlin, Deutschland und Cambridge, Massachusetts, USA, – 8. Januar 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) und ARTBIO, Inc. (ARTBIO), ein Biotechnologieunternehmen in der klinischen Phase, das sich auf die Entwicklung einer neuen Klasse von Alpha-Radioliganden-Therapien (ARTs) spezialisiert hat, haben eine strategische Herstellungs- u......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.01.2024
ISIN: DE0005659700
Eckert & Ziegler SE
EUZ
LISTED
XETR
Eckert & Ziegler and ARTBIO Announce Manufacturing and Supply Partnership for Lead-212 Conjugates
Article
News Preview
Berlin, Germany and Cambridge, Mass., – 8 January 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and ARTBIO, Inc. (ARTBIO), a clinical-stage biotechnology company specializing in the development of a new class of alpha radioligand therapies (ARTs), have entered into a strategic manufacturing and supply agreement. Under the collaboration Ecke......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.01.2024
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec verkündet Fortschritt in strategischer Neurologie-Partnerschaft mit Bristol Myers Squibb
Article
News Preview
WICHTIGER WISSENSCHAFTLICHER FORTSCHRITT BRINGT DIE GEMEINSAME NEUROLOGIE-PIPELINE VORAN UND LÖST EINE ZAHLUNG VON 25 MIO. $ AN EVOTEC AUS, UM DIE WEITERE FORSCHUNG VORANZUTREIBEN   Hamburg, 08. Januar 2024: Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) gab heute einen Fortschritt in der strategischen P......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.01.2024
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb
Article
News Preview
KEY SCIENTIFIC ACHIEVEMENT ADVANCES THE JOINT NEUROSCIENCE PIPELINE AND EARNS A PAYMENT OF US$ 25 M TO EVOTEC TO PROGRESS FURTHER RESEARCH   Hamburg, Germany, 08 January 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced progress within the Company’s strategic partnership with Bristol Myer......
Themefolio
Profiler
Peergroup
© EQS Newswire
07.01.2024
ISIN: NL0012169213
Qiagen NV
QGEN
LISTED
NYSE
QIAGEN to return approximately $300 million to shareholders through a synthetic share repurchase
Article
News Preview
Ad hoc Announcement according to Art. 17 Market Abuse Regulation QIAGEN to return approximately $300 million to shareholders through a synthetic share repurchase Venlo, the Netherlands, January 7, 2024 – QIAGEN N.V. announces a plan to return up to approximately $300 million (maximum EUR 273 million) to shareholders through a synthetic share repu......
Themefolio
Profiler
Peergroup
© EQS Newswire
07.01.2024
ISIN: NL0012169213
Qiagen NV
QGEN
LISTED
NYSE
QIAGEN zahlt rund 300 Millionen Dollar durch einen synthetischen Aktienrückkauf an seine Aktionärinnen und Aktionäre zurück
Article
News Preview
Ad-hoc-Mitteilung gemäß Art. 17 Marktmissbrauchsverordnung QIAGEN zahlt rund 300 Millionen Dollar durch einen synthetischen Aktienrückkauf an seine Aktionärinnen und Aktionäre zurück Venlo, Niederlande, 7. Januar 2024 – QIAGEN N.V. gibt Pläne bekannt, mittels eines synthetischen Aktienrückkaufs bis zu rund $300 Mio. (maximal EUR 273 Mio.) an Akti......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.01.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon to present at the 42nd Annual J.P. Morgan Healthcare Conference
Article
News Preview
Press Release // January 04, 2024   Formycon to present at the 42nd Annual J.P. Morgan Healthcare Conference Munich, Germany – Formycon AG (FSE: FYB), a leading, independent developer of high-quality biosimilars, today announced that Formycon CEO Dr. Stefan Glombitza will present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on T......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.01.2024
ISIN: DE000A1EWVY8
Formycon AG
FYB
LISTED
XETR
Formycon präsentiert auf der 42. Annual J.P. Morgan Healthcare Conference
Article
News Preview
Pressemitteilung // 04. Januar 2024   Formycon präsentiert auf der 42. Annual J.P. Morgan Healthcare Conference München – Die Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY), ein führender unabhängiger Entwickler qualitativ hochwertiger Biosimilars hat heute bekannt gegeben, dass Formycon CEO Dr. Stefan Glombitza bei der 42. Annual J.P. Morgan Hea......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.01.2024
ISIN: US4577301090
Inspire Medical Systems Inc
INSP
LISTED
NYSE
Kaplan Fox & Kilsheimer LLP Notifies Inspire Medical Investors of a Class Action Lawsuit and Upcoming Deadline
Article
News Preview
INSPIRE MEDICAL INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies Inspire Medical Investors of a Class Action Lawsuit and Upcoming Deadline NEW YORK, NY – January 4, 2024 – Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of purchasers of Inspire Medical Systems, Inc. (“Inspire Medical” or the “Co......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.01.2024
ISIN: DE000A0LD6E6
Gerresheimer AG
GXI
LISTED
XETR
Gerresheimer und Aptar Digital Health kooperieren zur Entwicklung einer integrierten Lösung für Krebstherapie
Article
News Preview
Gerresheimer und Aptar Digital Health kooperieren zur Entwicklung einer integrierten Lösung für Krebstherapie Subkutane Verabreichung von Krebsmedikamenten mit digitaler Therapieunterstützung Integration der Gx SensAir Medikamentenpumpe mit der Digital Health Plattform von Aptar Ziel: Lösung zur Verbesserung der Patientenerfahrung und Lebensqua......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.01.2024
ISIN: DE000A0LD6E6
Gerresheimer AG
GXI
LISTED
XETR
Gerresheimer and Aptar Digital Health collaborate to develop integrated solution for cancer therapy 
Article
News Preview
Gerresheimer and Aptar Digital Health collaborate to develop integrated solution for cancer therapy  Subcutaneous administration of oncology drugs with digital therapy support Integrating Gx SensAir drug delivery device with Aptar's Digital Health platform Solution aims to improve the patient experience and quality of life of cancer patients   D......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.01.2024
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec und Owkin gehen K.I.-gestützte strategische Partnerschaft zur Beschleunigung der therapeutischen Pipeline in den Bereichen Onkologie und I&I ein
Article
News Preview
PARTNERSCHAFT KOMBINIERT OWKINS FÄHIGKEITEN ZUR K.I.-GESTÜTZTEN ENTDECKUNG VON TARGETS MIT EVOTECS INTEGRIERTEN SHARED END-TO-END FORSCHUNGS- & ENTWICKLUNGS-PLATTFORM K.I.-GESTÜTZTE PLATTFORMEN WERDEN OWKINS NEUARTIGE PROGRAMME VON DER ENTDECKUNGSPHASE IN DIE KLINISCHE ENTWICKLUNG BESCHLEUNIGEN VEREINBARUNG UMFASST ERFOLGSABHÄNGIGE MEILENSTEI......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.01.2024
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec and Owkin enter an A.I.-powered strategic partnership to accelerate therapeutics pipeline in oncology and I&I
Article
News Preview
PARTNERSHIP COMBINES OWKIN’S A.I. TARGET DISCOVERY CAPABILITIES WITH EVOTEC’S INTEGRATED END-TO-END SHARED R&D PLATFORM A.I.-POWERED PLATFORMS WILL ACCELERATE OWKIN’S NOVEL PROGRAMMES FROM THE DISCOVERY PHASE TO THE CLINIC AGREEMENT INCLUDES SUCCESS-BASED MILESTONES AND ROYALTY PAYMENTS TO EVOTEC  Hamburg, Germany, and Paris, France, 04 Janu......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.01.2024
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec gibt CEO-Wechsel bekannt
Article
News Preview
DR. WERNER LANTHALER TRITT ALS VORSTANDSVORSITZENDER (CEO) ZURÜCK STEHT DEM AUFSICHTSRAT WEITERHIN ALS STRATEGISCHER BERATER ZUR VERFÜGUNG, UM EINE REIBUNGSLOSE ÜBERGABE ZU GEWÄHRLEISTEN DR. MARIO POLYWKA HAT ZUGESTIMMT, DAS AMT ALS CEO INTERIMISTISCH ZU ÜBERNEHMEN SUCHE FÜR EINEN LANGFRISTIGEN CEO GESTARTET, UM DEN AUFBAU DES WELTWEIT FÜHRENDEN......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.01.2024
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec announces CEO transition
Article
News Preview
DR WERNER LANTHALER TO STEP DOWN AS CEO REMAINS AVAILABLE AS STRATEGIC ADVISOR TO THE SUPERVISORY BOARD TO FACILITATE A SMOOTH TRANSITION DR MARIO POLYWKA HAS AGREED TO STEP IN AS INTERIM CEO SEARCH STARTED FOR PERMANENT CEO TO CONTINUE BUILDING THE GLOBALLY LEADING COMPANY FOR EXTERNAL INNOVATION EVOTEC CONFIRMS GUIDANCE 2023 Hamburg, Germany......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.01.2024
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec gibt CEO-Wechsel bekannt
Article
News Preview
Hamburg, Deutschland, – Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) gibt bekannt, dass Vorstandsvorsitzender Dr. Werner Lanthaler dem Unternehmen mitgeteilt hat, dass er aus persönlichen Gründen als CEO zurücktritt und seinen Vertrag nicht bis zum Ende der aktuellen Laufz......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.01.2024
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec announces CEO transition
Article
News Preview
Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that CEO Dr Werner Lanthaler has informed the company, that he has decided to step down as CEO and will not continue to serve until the end of his current term, for personal reasons. The Supervisory Bo......
Themefolio
Profiler
Peergroup
© Newsfile
11.12.2023
ISIN: NL0011832936
Cosmo Pharmaceuticals NV
COPN
LISTED
SIX
Cosmo Pharmaceuticals and Medtronic Forge Ahead in AI-Driven Care
Article
News Preview
Agreement Expands Partnership Between Cosmo Pharmaceuticals and Medtronic, Set to Transform Endoscopy with Cutting-Edge AI Technology Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - December 11, 2023) - Cosmo Pharmaceuticals (SIX: COPN) (XETRA: C43) (“Cosmo”) announces that its subsi...
Themefolio
Profiler
Peergroup
© Newsfile
08.12.2023
ISIN: US83086J2006
Skye Bioscience Inc
SKYE
LISTED
NASDAQ
Skye Bioscience Responds to OTC Markets Promotional Policy
Article
News Preview
San Diego, California--(Newsfile Corp. - December 8, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing drugs targeting the endocannabinoid system, focusing on metabolic conditions and glaucoma, has received a request by OTC Markets Group Inc. ("OTC Markets") to issue this statement about prom...
Themefolio
Profiler
Peergroup
© Newsfile
05.12.2023
ISIN: US83086J2006
Skye Bioscience Inc
SKYE
LISTED
NASDAQ
Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa
Article
News Preview
San Diego, California and Johannesburg, South Africa--(Newsfile Corp. - December 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs targeting the endocannabinoid system, and Tautomer Bioscience (Pty) Limited ("Tautomer"), a privately-owned biopharmaceutical company focused on addressing unmet medical...
Themefolio
Profiler
Peergroup
© Newsfile
21.11.2023
ISIN: US83086J2006
Skye Bioscience Inc
SKYE
LISTED
NASDAQ
Skye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit
Article
News Preview
San Diego, California--(Newsfile Corp. - November 21, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs targeting the endocannabinoid system to address diseases including glaucoma and metabolic conditions, will present an overview of its glaucoma program at two ophthalmology-focused conferences. Company...
Themefolio
Profiler
Peergroup
© Newsfile
25.10.2023
ISIN: US83086J2006
Skye Bioscience Inc
SKYE
LISTED
NASDAQ
Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma
Article
News Preview
• SBI-100 OE is well tolerated, with low rate of hyperaemia (8.4%)• Reduced intraocular pressure (23% mean reduction) in healthy volunteers with higher baseline IOP (>17 mm Hg)San Diego, California--(Newsfile Corp. - October 25, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Themefolio
Profiler
Peergroup
© Newsfile
25.05.2020
ISIN: US0327241065
AnaptysBio Inc
ANAB
LISTED
NASDAQ
ANAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 26, 2020 in the Class Action Filed on Behalf of AnaptysBio, Inc. Limited Shareholders
Article
News Preview
New York, New York--(Newsfile Corp. - May 25, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of AnaptysBio, Inc. (NASDAQ: ANAB) alleging that the Company violated federal securities laws.Class Period: October 10, 2017 and November 7, 2019Lead Plaintiff Deadline: May 26, 2020Learn more abo...
Themefolio
Profiler
Peergroup
© Newsfile
25.05.2020
ISIN: US0327241065
AnaptysBio Inc
ANAB
LISTED
NASDAQ
DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AnaptysBio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Article
News Preview
Los Angeles, California--(Newsfile Corp. - May 25, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AnaptysBio, Inc. ("AnaptysBio" or "the Company") (NASDAQ: ANAB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-...
Themefolio
Profiler
Peergroup
© Newsfile
25.05.2020
ISIN: US0327241065
AnaptysBio Inc
ANAB
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AnaptysBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 26, 2020 - ANAB
Article
News Preview
New York, New York--(Newsfile Corp. - May 25, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of AnaptysBio, Inc. (NASDAQ: ANAB) ("AnaptysBio, Inc.")  between October 10, 2017 and November 7, 2019. You are hereby notified that a securities c...
Themefolio
Profiler
Peergroup
© Newsfile
22.05.2020
ISIN: US0327241065
AnaptysBio Inc
ANAB
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AnaptysBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 26, 2020 - ANAB
Article
News Preview
New York, New York--(Newsfile Corp. - May 22, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of AnaptysBio, Inc. (NASDAQ: ANAB) ("AnaptysBio, Inc.") between October 10, 2017 and November 7, 2019. You are hereby notified that a securiti...
Themefolio
Profiler
Peergroup
© Newsfile
22.05.2020
ISIN: US0327241065
AnaptysBio Inc
ANAB
LISTED
NASDAQ
ANAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 26, 2020 in the Class Action Filed on Behalf of AnaptysBio, Inc. Limited Shareholders
Article
News Preview
New York, New York--(Newsfile Corp. - May 22, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of AnaptysBio, Inc. (NASDAQ: ANAB) alleging that the Company violated federal securities laws.Class Period: October 10, 2017 and November 7, 2019Lead Plaintiff Deadline: May 26, 2020Learn more abo...
Themefolio
Profiler
Peergroup
© Newsfile
21.05.2020
ISIN: US0327241065
AnaptysBio Inc
ANAB
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AnaptysBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 26, 2020 - ANAB
Article
News Preview
New York, New York--(Newsfile Corp. - May 21, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of AnaptysBio, Inc. ("AnaptysBio, Inc.") (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019. You are hereby notified that a securities class a...
Themefolio
Profiler
Peergroup
© Newsfile
21.05.2020
ISIN: US0327241065
AnaptysBio Inc
ANAB
LISTED
NASDAQ
ANAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 26, 2020 in the Class Action Filed on Behalf of AnaptysBio, Inc. Limited Shareholders
Article
News Preview
New York, New York--(Newsfile Corp. - May 21, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of AnaptysBio, Inc. (NASDAQ: ANAB) alleging that the Company violated federal securities laws.Class Period: October 10, 2017 and November 7, 2019Lead Plaintiff Deadline: May 26, 2020Learn more abo...
Themefolio
Profiler
Peergroup
© Newsfile
20.05.2020
ISIN: US0327241065
AnaptysBio Inc
ANAB
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AnaptysBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 26, 2020 - ANAB
Article
News Preview
New York, New York--(Newsfile Corp. - May 20, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of AnaptysBio, Inc. (NASDAQ: ANAB) ("AnaptysBio, Inc.") between October 10, 2017 and November 7, 2019. You are hereby notified that a securiti...
Themefolio
Profiler
Peergroup
© Newsfile
20.05.2020
ISIN: US0327241065
AnaptysBio Inc
ANAB
LISTED
NASDAQ
AnaptysBio Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In AnaptysBio, Inc. To Contact The Firm
Article
News Preview
New York, New York--(Newsfile Corp. - May 20, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. ("Anaptys" or the "Company") (NASDAQ: ANAB) of the May 26, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi...
Themefolio
Profiler
Peergroup
© Newsfile
19.05.2020
ISIN: US0327241065
AnaptysBio Inc
ANAB
LISTED
NASDAQ
ANAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 26, 2020 in the Class Action Filed on Behalf of AnaptysBio, Inc. Limited Shareholders
Article
News Preview
New York, New York--(Newsfile Corp. - May 19, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of AnaptysBio, Inc. (NASDAQ: ANAB) alleging that the Company violated federal securities laws.Class Period: October 10, 2017 and November 7, 2019Lead Plaintiff Deadline: May 26, 2020Learn more abo...
Themefolio
Profiler
Peergroup
© Newsfile
19.05.2020
ISIN: US0327241065
AnaptysBio Inc
ANAB
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AnaptysBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 26, 2020 - ANAB
Article
News Preview
New York, New York--(Newsfile Corp. - May 19, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of AnaptysBio, Inc. (NASDAQ: ANAB) ("AnaptysBio, Inc.") between October 10, 2017 and November 7, 2019. You are hereby notified that a securiti...
Themefolio
Profiler
Peergroup
© Newsfile
18.05.2020
ISIN: NL0012169213
Qiagen NV
QGEN
LISTED
NYSE
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of QIAGEN N.V. to Thermo Fisher Scientific Inc. is Fair to Shareholders
Article
News Preview
New York, New York--(Newsfile Corp. - May 18, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased QIAGEN N.V. (NYSE: QGEN) ("QIAGEN" or the "Company") stock prior to May 18, 2020.You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness...
Themefolio
Profiler
Peergroup
© Newsfile
17.05.2020
ISIN: US0327241065
AnaptysBio Inc
ANAB
LISTED
NASDAQ
AnaptysBio Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In AnaptysBio, Inc. To Contact The Firm
Article
News Preview
New York, New York--(Newsfile Corp. - May 17, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AnaptysBio, Inc. ("Anaptys" or the "Company") (NASDAQ: ANAB) of the May 26, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi...
Themefolio
Profiler
Peergroup
© Newsfile
15.05.2020
ISIN: US0327241065
AnaptysBio Inc
ANAB
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AnaptysBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 26, 2020 - ANAB
Article
News Preview
New York, New York--(Newsfile Corp. - May 15, 2020) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of AnaptysBio, Inc. ("AnaptysBio, Inc.") (NASDAQ: ANAB) between October 10, 2017 and November 7, 2019. You are hereby notified that a securities c...
Themefolio
Profiler
Peergroup
© Newsfile
14.05.2020
ISIN: US0327241065
AnaptysBio Inc
ANAB
LISTED
NASDAQ
ANAB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 26, 2020 in the Class Action Filed on Behalf of AnaptysBio, Inc. Limited Shareholders
Article
News Preview
New York, New York--(Newsfile Corp. - May 14, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of AnaptysBio, Inc. (NASDAQ: ANAB) alleging that the Company violated federal securities laws.Klein Law Firm LogoClass Period: October 10, 2017 and November 7, 2019Lead Plaintiff Deadline: May 26...
Themefolio
Profiler
Peergroup
© Newsfile
14.05.2020
ISIN: US0327241065
AnaptysBio Inc
ANAB
LISTED
NASDAQ
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AnaptysBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 26, 2020 - ANAB
Article
News Preview
New York, New York--(Newsfile Corp. - May 14, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of AnaptysBio, Inc. (NASDAQ: ANAB) ("AnaptysBio, Inc.") between October 10, 2017 and November 7, 2019. You are hereby notified that a securiti...
Themefolio
Profiler
Peergroup
© Newsfile
08.05.2020
ISIN: GB00B7FC0762
NMC Health plc
NMMCF
LISTED
OTC
NMC Class Action Reminder: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in NMC Health Plc to Contact the Firm
Article
News Preview
New York, New York--(Newsfile Corp. - May 8, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in NMC Health Plc (OTC Pink: NMHLY) ("NMC" or the "Company") of the May 11, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faru...
Themefolio
Profiler
Peergroup
© Newsfile
07.05.2020
ISIN: GB00B7FC0762
NMC Health plc
NMMCF
LISTED
OTC
NMC Shareholder Notice: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In NMC Health Plc To Contact The Firm
Article
News Preview
New York, New York--(Newsfile Corp. - May 7, 2020) -   Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in NMC Health Plc ("NMC" or the "Company") (OTC Pink: NMHLY) of the May 11, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Far...
Themefolio
Profiler
Peergroup
© Newsfile
06.05.2020
ISIN: GB00B7FC0762
NMC Health plc
NMMCF
LISTED
OTC
NMC Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in NMC Health Plc to Contact the Firm
Article
News Preview
New York, New York--(Newsfile Corp. - May 6, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in NMC Health Plc  (OTC Pink: NMHLY) ("NMC" or the "Company") of the May 11, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company...
Themefolio
Profiler
Peergroup
© Newsfile
05.05.2020
ISIN: GB00B7FC0762
NMC Health plc
NMMCF
LISTED
OTC
NMC Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In NMC Health Plc To Contact The Firm
Article
News Preview
New York, New York--(Newsfile Corp. - May 5, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in NMC Health Plc ("NMC" or the "Company") (OTC Pink: NMHLY) of the May 11, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faru...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Friday, 23.01.2026, Calendar Week 04, 23rd day of the year, 342 days remaining until EoY.